PHARMA NORD ApS: Financial statements 2021
CVR: 67303016
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 470,180,000 and a net result of DKK 57,966,000 compared with DKK 51,949,000 the year before. That is an increase of 12.7% compared with the year before. The profit margin was 12.3%. Equity in the 2021 report amounted to DKK 199,348,000. The solvency ratio was 43.3%. The company had 420 employees in the financial year.
- Revenue
- DKK 470,180,000
- Gross Profit
- DKK 221,003,000
- Profit/Loss
- DKK 57,966,000
- Equity
- DKK 199,348,000
- Total Assets
- DKK 460,569,000
- Employees
- 420
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 470.2 mio. | 221 mio. | 58 mio. | 199.3 mio. | 420 |
| 2020 | 417.2 mio. | 197.9 mio. | 51.9 mio. | 170.4 mio. | 394 |
| 2019 | 333 mio. | 126.1 mio. | 41.5 mio. | 269.7 mio. | 375 |
| 2018 | 334 mio. | 132.3 mio. | 37.7 mio. | 212.7 mio. | 364 |
| 2017 | 343.1 mio. | 135.4 mio. | 46.8 mio. | 181.9 mio. | 378 |
Official annual report
Find more companies like PHARMA NORD ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
PHARMA NORD ApS has published its annual report for 2020. Revenue came to DKK 417,178,000, and the net result was DKK 51,949,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.